Medical education company Pri-Med said on Tuesday that it has entered into a new partnership with the Brain Aneurysm Foundation (BAF) to deliver "Update in Diagnosis and Management of Intracranial Aneurysms for Primary Health Care Providers" at Pri-Med Midwest in Rosemont, IL on 10 October 2018.
During the medical session, Sepideh Amin-Hanjani, MD, University of Illinois at Chicago, will address how to recognise signs of an aneurysm rupture, when to make a referral and order appropriate imaging, and best practices for educating the patient about the risk factors for aneurysm formation and rupture.
According to the company, one in 50 people in the US has an unruptured brain aneurysm and 30,000 of them rupture every year. Despite low frequency, brain aneurysms are high in mortality, because the lack of a timely diagnosis often leads to death.
This session will focus on the importance of proper diagnosis and scanning and faculty will discuss treatment options to use in practice to meet the need for early detection of brain aneurysm.
Brain Aneurysm Foundation (BAF) is a non-profit organization dedicated to providing critical awareness, education, support, advocacy, and research funding to reduce the incidence of brain aneurysm ruptures.
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial